Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2

Managing insulin resistance: role of liraglutide

Authors Kalra S, Kalra B, Kumar S, Sharma A

Published 24 June 2010 Volume 2010:2 Pages 131—134

DOI https://doi.org/10.2147/CPAA.S10496

Review by Single anonymous peer review

Peer reviewer comments 3


Sanjay Kalra1, Bharti Kalra1, Satish Kumar2, Amit Sharma1

1Department of Endocrinology, Bharti Hospital, Karnal, India; 2Department of Clinical Operations, Excel Life Sciences, Noida, India

Abstract: Diabetes mellitus is part of the insulin resistance syndrome, which includes hypertension, dyslipidemia, and obesity as its other components. Conversely, insulin resistance is a major pathophysiologic factor in the development of type 2 diabetes. It makes sense, therefore, to choose an anti-diabetic medication that acts on insulin resistance and its clinical components, while having anti-hyperglycemic effects as well. This review discusses the non-glycemic, or extra-pancreatic effects, including insulin sensitization, of liraglutide, a novel GLP-1 analog.

Keywords: liraglutide, GLP-1 analog, weight modulation, systolic blood pressure, cardioprotection, insulin resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]